Vaccination with a ZNF2oe Strain of Cryptococcus Provides Long-Lasting Protection against Cryptococcosis and Is Effective in Immunocompromised Hosts
Systemic cryptococcosis is fatal without treatment. Even with the current antifungal therapies,
this disease kills 180,000 of 225,000 infected people annually. Exposure to the causative …
this disease kills 180,000 of 225,000 infected people annually. Exposure to the causative …
Immunoprotection against cryptococcosis offered by znf2 depends on capsule and the hyphal morphology
Systemic cryptococcosis is fatal without treatment. Globally, this disease kills 180,000 of the
225,000 infected people each year, even with the use of antifungal therapies. Currently …
225,000 infected people each year, even with the use of antifungal therapies. Currently …
Induction of Broad-Spectrum Protective Immunity against Disparate Cryptococcus Serotypes
Cryptococcosis is a fungal disease caused by multiple Cryptococcus serotypes; particularly
C. neoformans (serotypes A and D) and C. gattii (serotypes B and C). To date, there is no …
C. neoformans (serotypes A and D) and C. gattii (serotypes B and C). To date, there is no …
A call to arms: quest for a cryptococcal vaccine
MCC Van Dyke, FL Wormley - Trends in microbiology, 2018 - cell.com
Cryptococcosis remains a significant cause of morbidity and mortality world-wide,
particularly among AIDS patients. Yet, to date, there are no licensed vaccines clinically …
particularly among AIDS patients. Yet, to date, there are no licensed vaccines clinically …
[PDF][PDF] Vaccination with recombinant Cryptococcus proteins in glucan particles protects mice against cryptococcosis in a manner dependent upon mouse strain and …
CA Specht, CK Lee, H Huang, MM Hester, J Liu… - 2017 - core.ac.uk
Development of a vaccine to protect against cryptococcosis is a priority given the enormous
global burden of disease in at-risk individuals. Using glucan particles (GPs) as a delivery …
global burden of disease in at-risk individuals. Using glucan particles (GPs) as a delivery …
Promising whole‐cell vaccines against cryptococcosis
K Ueno, S Tsuge, K Shimizu… - Microbiology and …, 2023 - Wiley Online Library
Cryptococcosis is a mycosis caused by Cryptococcus neoformans and C. gattii species
complexes. Although this infection is potentially lethal, no prophylactic vaccine is yet …
complexes. Although this infection is potentially lethal, no prophylactic vaccine is yet …
Three Models of Vaccination Strategies Against Cryptococcosis in Immunocompromised Hosts Using Heat-Killed Cryptococcus neoformans Δsgl1
TG Normile, M Del Poeta - Frontiers in Immunology, 2022 - frontiersin.org
Vaccines are one of the greatest medical accomplishments to date, yet no fungal vaccines
are currently available in humans mainly because opportunistic mycoses generally occur …
are currently available in humans mainly because opportunistic mycoses generally occur …
Towards a vaccine for Cryptococcus neoformans: principles and caveats
K Datta, L Pirofski - FEMS yeast research, 2006 - academic.oup.com
In the Damage-response framework of microbial pathogenesis, infectious diseases are one
outcome of a host-microorganism interaction in a susceptible host. In cryptococcal disease …
outcome of a host-microorganism interaction in a susceptible host. In cryptococcal disease …
Vaccine and immunotherapeutic approaches for the prevention of cryptococcosis: lessons learned from animal models
CR Hole, FL Wormley Jr - Frontiers in microbiology, 2012 - frontiersin.org
Cryptococcus neoformans and C. gattii, the predominant etiological agents of
cryptococcosis, can cause life-threatening infections of the central nervous system in …
cryptococcosis, can cause life-threatening infections of the central nervous system in …
Vaccination with Recombinant Cryptococcus Proteins in Glucan Particles Protects Mice against Cryptococcosis in a Manner Dependent upon Mouse Strain and …
CA Specht, CK Lee, H Huang, MM Hester, J Liu… - MBio, 2017 - Am Soc Microbiol
Development of a vaccine to protect against cryptococcosis is a priority given the enormous
global burden of disease in at-risk individuals. Using glucan particles (GPs) as a delivery …
global burden of disease in at-risk individuals. Using glucan particles (GPs) as a delivery …